Our Work

Latham & Watkins Advises on Financing for EQT’s US$2.1 Billion Bid to Acquire Recipharm

December 15, 2020

Finance and capital markets team acts on private equity firm’s purchase of listed Swedish pharmaceuticals company.

Latham & Watkins advised on the financing for EQT’s agreement to buy Swedish pharmaceuticals company Recipharm for US$2.1 billion (SEK17.9 billion).

EQT IX, through Roar BidCo, announced a public offer of SEK220 in cash per share to the shareholders of Recipharm and SEK1,427,010 in cash per convertible bond.

Financing for the offer was led by London partners Dominic Newcomb and Jennifer Engelhardt, with counsel Will Lam and associates Melanie Emmen and Medha Vikram. Advice on convertible bonds was provided by London capital markets partner Manoj Tulsiani and associate Amina Tsatiashvili.

Endnotes

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.